Pharmacotherapy of insomnia with ramelteon : safety, efficacy and clinical applications
Abstract: Ramelteon is a tricyclic synthetic analog of melatonin that acts specifically on MT1 and MT2 melatonin receptors. Ramelteon is the first melatonin receptor agonist approved by the Food and Drug Administration (FDA) for the treatment of insomnia characterized by sleep onset difficulties. Ramelteon is both a chronobiotic and a hypnotic that has been shown to promote sleep initiation and maintenance in various preclinical and in clinical trials. The efficacy and safety of ramelteon in patients with chronic insomnia was initially confirmed in short-term placebo-controlled trials. These showed little evidence of next-day residual effects, withdrawal symptoms or rebound insomnia. Other studies indicated that ramelteon lacked abuse potential and had a minimal risk of producing dependence or adverse effects on cognitive or psychomotor performance. A 6-month placebo-controlled international study and a 1-year open-label study in the USA demonstrated that ramelteon was effective and well tolerated. Other potential off-label uses of ramelteon include circadian rhythm sleep disorders such as shift-work and jet lag. At the present time the drug should be cautiously prescribed for short-term treatment only.
Main Authors: | , , , , , , |
---|---|
Format: | Artículo biblioteca |
Language: | eng eng |
Published: |
Libertas Academica
2011
|
Subjects: | RITMO CIRCADIANO, MELATONINA, RAMELTEON, SUEÑO, INSOMNIO, HIPNOTICOS Y SEDANTES, |
Online Access: | https://repositorio.uca.edu.ar/handle/123456789/1646 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
oai:ucacris:123456789-1646 |
---|---|
record_format |
koha |
spelling |
oai:ucacris:123456789-16462020-07-29T22:09:35Z Pharmacotherapy of insomnia with ramelteon : safety, efficacy and clinical applications Pandi Perumal, Seithikurippu R. Spence, David Warren Verster, Joris C. Srinivasan, Venkataramanujan Brown, Gregory M. Cardinali, Daniel Pedro Hardeland, Rüdiger RITMO CIRCADIANO MELATONINA RAMELTEON SUEÑO INSOMNIO HIPNOTICOS Y SEDANTES Abstract: Ramelteon is a tricyclic synthetic analog of melatonin that acts specifically on MT1 and MT2 melatonin receptors. Ramelteon is the first melatonin receptor agonist approved by the Food and Drug Administration (FDA) for the treatment of insomnia characterized by sleep onset difficulties. Ramelteon is both a chronobiotic and a hypnotic that has been shown to promote sleep initiation and maintenance in various preclinical and in clinical trials. The efficacy and safety of ramelteon in patients with chronic insomnia was initially confirmed in short-term placebo-controlled trials. These showed little evidence of next-day residual effects, withdrawal symptoms or rebound insomnia. Other studies indicated that ramelteon lacked abuse potential and had a minimal risk of producing dependence or adverse effects on cognitive or psychomotor performance. A 6-month placebo-controlled international study and a 1-year open-label study in the USA demonstrated that ramelteon was effective and well tolerated. Other potential off-label uses of ramelteon include circadian rhythm sleep disorders such as shift-work and jet lag. At the present time the drug should be cautiously prescribed for short-term treatment only. 2019-05-02T14:01:15Z 2019-05-02T14:01:15Z 2011 Artículo Pandi-Perumal, S. R., et al. Pharmacotherapy of insomnia with ramelteon : safety, efficacy and clinical applications. Journal of Central Nervous System Disease. 2011, 3. doi:10.4137/JCNSD.S1611. Disponible en: https://repositorio.uca.edu.ar/handle/123456789/1646 1179-5735 (online) 1179-5735 (impreso) https://repositorio.uca.edu.ar/handle/123456789/1646 10.4137/JCNSD.S1611 eng eng Acceso Abierto https://creativecommons.org/licenses/by-nc-sa/4.0/ application/pdf Libertas Academica Journal of Central Nervous System Disease. 2011, 3 |
institution |
UCA |
collection |
DSpace |
country |
Argentina |
countrycode |
AR |
component |
Bibliográfico |
access |
En linea |
databasecode |
dig-uca |
tag |
biblioteca |
region |
America del Sur |
libraryname |
Sistema de bibliotecas de la UCA |
language |
eng eng |
topic |
RITMO CIRCADIANO MELATONINA RAMELTEON SUEÑO INSOMNIO HIPNOTICOS Y SEDANTES RITMO CIRCADIANO MELATONINA RAMELTEON SUEÑO INSOMNIO HIPNOTICOS Y SEDANTES |
spellingShingle |
RITMO CIRCADIANO MELATONINA RAMELTEON SUEÑO INSOMNIO HIPNOTICOS Y SEDANTES RITMO CIRCADIANO MELATONINA RAMELTEON SUEÑO INSOMNIO HIPNOTICOS Y SEDANTES Pandi Perumal, Seithikurippu R. Spence, David Warren Verster, Joris C. Srinivasan, Venkataramanujan Brown, Gregory M. Cardinali, Daniel Pedro Hardeland, Rüdiger Pharmacotherapy of insomnia with ramelteon : safety, efficacy and clinical applications |
description |
Abstract: Ramelteon is a tricyclic synthetic analog of melatonin that acts specifically on MT1 and MT2 melatonin receptors. Ramelteon is the first melatonin receptor agonist approved by the Food and Drug Administration (FDA) for the treatment of insomnia characterized by sleep onset difficulties. Ramelteon is both a chronobiotic and a hypnotic that has been shown to promote sleep initiation and maintenance in various preclinical and in clinical trials. The efficacy and safety of ramelteon in patients with chronic insomnia was initially confirmed in short-term placebo-controlled trials. These showed little evidence of next-day residual effects, withdrawal symptoms or rebound insomnia. Other studies indicated that ramelteon lacked abuse potential and had a minimal risk of producing dependence or adverse effects on cognitive or psychomotor performance. A 6-month placebo-controlled international study and a 1-year open-label study in the USA demonstrated that ramelteon was effective and well tolerated. Other potential off-label uses of ramelteon include circadian rhythm sleep disorders such as shift-work and jet lag. At the present time the drug should be cautiously prescribed for short-term treatment only. |
format |
Artículo |
topic_facet |
RITMO CIRCADIANO MELATONINA RAMELTEON SUEÑO INSOMNIO HIPNOTICOS Y SEDANTES |
author |
Pandi Perumal, Seithikurippu R. Spence, David Warren Verster, Joris C. Srinivasan, Venkataramanujan Brown, Gregory M. Cardinali, Daniel Pedro Hardeland, Rüdiger |
author_facet |
Pandi Perumal, Seithikurippu R. Spence, David Warren Verster, Joris C. Srinivasan, Venkataramanujan Brown, Gregory M. Cardinali, Daniel Pedro Hardeland, Rüdiger |
author_sort |
Pandi Perumal, Seithikurippu R. |
title |
Pharmacotherapy of insomnia with ramelteon : safety, efficacy and clinical applications |
title_short |
Pharmacotherapy of insomnia with ramelteon : safety, efficacy and clinical applications |
title_full |
Pharmacotherapy of insomnia with ramelteon : safety, efficacy and clinical applications |
title_fullStr |
Pharmacotherapy of insomnia with ramelteon : safety, efficacy and clinical applications |
title_full_unstemmed |
Pharmacotherapy of insomnia with ramelteon : safety, efficacy and clinical applications |
title_sort |
pharmacotherapy of insomnia with ramelteon : safety, efficacy and clinical applications |
publisher |
Libertas Academica |
publishDate |
2011 |
url |
https://repositorio.uca.edu.ar/handle/123456789/1646 |
work_keys_str_mv |
AT pandiperumalseithikurippur pharmacotherapyofinsomniawithramelteonsafetyefficacyandclinicalapplications AT spencedavidwarren pharmacotherapyofinsomniawithramelteonsafetyefficacyandclinicalapplications AT versterjorisc pharmacotherapyofinsomniawithramelteonsafetyefficacyandclinicalapplications AT srinivasanvenkataramanujan pharmacotherapyofinsomniawithramelteonsafetyefficacyandclinicalapplications AT browngregorym pharmacotherapyofinsomniawithramelteonsafetyefficacyandclinicalapplications AT cardinalidanielpedro pharmacotherapyofinsomniawithramelteonsafetyefficacyandclinicalapplications AT hardelandrudiger pharmacotherapyofinsomniawithramelteonsafetyefficacyandclinicalapplications |
_version_ |
1756275065478971392 |